. . "Absorbed rapidly. Food increases the extent of absorption by 30% to 85%."@en . . . . "withdrawn"@en . . . . . . . . . . . . "# Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P: Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab. 2001 Jul;86(7):3250-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11443197"@en . . . . . "Humans and other mammals"@en . . . . . . . . "Troglitazone"@en . . . . . . . "> 99% (primarily to serum albumin)"@en . . . . . "97322-87-7"@en . "Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone."@en . . . . "Troglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin. It has a unique mechanism of action that is dependent on the presence of insulin for activity. Troglitazone decreases hepatic glucose output and increases insulin dependent glucose disposal in skeletal muscle. Its mechanism of action is thought to involve binding to nuclear receptors (PPAR) that regulate the transcription of a number of insulin responsive genes critical for the control of glucose and lipid metabolism. Troglitazone is a ligand to both PPAR\u03B1 and PPAR\u03B3, with a highter affinity for PPAR\u03B3. The drug also contains an \u03B1-tocopheroyl moiety, potentially giving it vitamin E-like activity. Troglitazone has been shown to reduce inflammation, and is associated with a decrase in nuclear factor kappa-B (NF-\u03BAB) and a concomitant increase in its inhibitor (I\u03BAB). NF-\u03BAB is an important cellular transcription regulator for the immune response. Unlike sulfonylureas, troglitazone is not an insulin secretagogue."@en . . . . . . "For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise."@en . "Krishnamurthi Vyas, Chebiyyam Prabhakar, Sreenivas Dharmaraja Rao, Mamillapalli Ramabadhra Sarma, Om Gaddam Reddy, Rajagopalan Ramanujam, Ranjan Chakrabarti, \"Polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation.\" U.S. Patent US5700820, issued June, 1992."@en . . . "16-34 hours"@en . .